Compare HTBK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | XNCR |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.7M | 881.9M |
| IPO Year | 1998 | 2013 |
| Metric | HTBK | XNCR |
|---|---|---|
| Price | $13.45 | $12.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $12.88 | ★ $22.33 |
| AVG Volume (30 Days) | 682.5K | ★ 798.3K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | 18.18 | ★ 65.36 |
| EPS | ★ 0.78 | N/A |
| Revenue | $3,688,000.00 | ★ $125,576,000.00 |
| Revenue This Year | $7.80 | N/A |
| Revenue Next Year | $5.51 | $4.80 |
| P/E Ratio | $17.24 | ★ N/A |
| Revenue Growth | 3.57 | ★ 13.65 |
| 52 Week Low | $8.74 | $6.92 |
| 52 Week High | $13.83 | $18.69 |
| Indicator | HTBK | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 56.48 |
| Support Level | $11.85 | $12.29 |
| Resistance Level | $13.65 | $12.87 |
| Average True Range (ATR) | 0.31 | 0.72 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 81.90 | 75.11 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. Majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.